Full-Time

Vice President

US Marketing

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$269.6k - $370.7k/yr

+ Annual bonus

Boston, MA, USA

Hybrid

Three days on-site per week, Tuesday through Thursday, or more depending on business needs.

Bachelor's, MBA

Category
Growth & Marketing (1)

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in business or a related discipline.
  • At least 10 years of experience within the pharmaceutical or biotechnology industries.
  • At least 7 years of related experience in leadership roles in marketing, sales, or other commercial functions, including brand leadership, in-line marketing, specialty marketing, and profit-and-loss management experience.
  • At least 5 years of people leadership experience, including at least 1 year managing multiple functions.
  • Experience managing commercial partnerships and co-promotions.
  • A demonstrated track record of successfully managing and developing teams in sales, marketing, and related commercial functions.
  • Strong matrix leadership and general management capabilities.
  • Recent experience leading teams and self in high-growth, fast-paced, start-up-like environments.
  • Refined executive presentation skills.
  • The ability to engage, influence, and navigate senior and complex stakeholders.
  • The ability to manage multiple stakeholders to achieve shared objectives.
  • The ability to motivate and develop a team.
  • The ability to advise and coach colleagues.
  • The ability to operate in an evolving environment, innovate creatively, influence and deliver in ambiguous environments, learn quickly, and execute strategically and operationally.
  • Willingness to travel 50% of the time.
Responsibilities
  • Lead the US marketing strategy and deliver the US profit and loss.
  • Help set the direction, culture, and focus for the Commercial Organization and support key strategic decisions.
  • Manage the annual US revenue and operating plans and secure investments to achieve performance and growth targets for inline and launch brands.
  • Establish relationships with patient, advocacy, and clinician communities and promote the Company as a partner of choice with major stakeholders.
  • Serve as the internal subject matter expert on emerging trends in the US healthcare ecosystem and their impact on rare disease and oncology management.
  • Drive prioritized focus toward patient identification, removal of barriers, and enablement of access to care.
  • Provide subject matter expertise and thought leadership to support decision-making on critical business challenges and opportunities shaping the commercial business, and brief executive management on relevant US market developments.
  • Drive the vision, design, and development of US marketing capabilities, including roles, accountabilities, and systems, and ensure the marketing function is appropriately scaled.
  • Provide vision for US Commercial Organization marketing and brand-management efforts by driving engagement and alignment across Commercial sub-teams, Medical, Supply Chain, Corporate Affairs, Legal and Compliance, Regulatory, and other stakeholders.
  • Shape launch-planning excellence and go-to-market strategies for the US.
  • Advise on US product-label development and competitive positioning of rare disease and oncology products.
  • Hire, mentor, and develop talent in alignment with business needs and succession goals for Commercial and the broader Company.
  • Ensure US Commercial strategy reflects the voice of US patients and customers through oversight of insights and strategy development and partnerships with key healthcare stakeholders.
  • Manage the US profit and loss, including revenue growth and stability, monthly and annual financial goals, margin, and profitability.
  • Partner with global teams and represent the US in business-development, in-licensing, and life-cycle-management opportunities.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • An MBA or other advanced degree.
  • Field experience.
  • Recent US launch experience in rare disease and/or oncology.
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • European Commission approved EZMEKLY on July 18, 2025, expanding mirdametinib revenue.
  • Merck's commercial network should accelerate global launches and payer access in 2026.
  • Rare-tumor assets fit Merck's strategy, increasing funding stability versus standalone biotech volatility.

What critics are saying

  • SpringWorks delisted after July 1, 2025; employees lost public-equity upside and visibility.
  • Merck controls pipeline priorities, so niche programs face portfolio pruning after 2026 reviews.
  • Heavy reliance on mirdametinib and nirogacestat creates single-franchise concentration risk if adoption stalls.

What makes SpringWorks Therapeutics unique

  • Nirogacestat and mirdametinib target rare tumors with first-in-class U.S. approvals.
  • SpringWorks built deep expertise in desmoid tumors and NF1-PN, underserved orphan markets.
  • Merck KGaA bought SpringWorks on July 1, 2025, validating its franchise value.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

6%

2 year growth

7%
AD HOC NEWS
May 21st, 2026
SpringWorks Therapeutics agrees to cash merger with $3.52B market cap desmoid tumor franchise

SpringWorks Therapeutics has completed a cash merger, according to a Robinhood corporate actions update from May 2026. The Nasdaq-listed biotech, which traded at $46.99 with a market capitalisation of approximately $3.52 billion as of mid-May, focuses on developing targeted therapies for rare diseases and oncology. The company's lead asset is nirogacestat, a gamma-secretase inhibitor for desmoid tumours, addressing significant unmet medical needs in this rare soft-tissue condition. SpringWorks also develops mirdametinib, a MEK inhibitor targeting neurofibromatosis type 1 plexiform neurofibromas. As a clinical-stage company, SpringWorks currently reports negative earnings, reflecting ongoing development costs typical of pre-commercial biotechnology firms. The company operates within the US-centred biotech ecosystem, with most clinical trials and regulatory interactions based in the United States.

AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.